NYSE:BVS Bioventus (BVS) Stock Price, News & Analysis $7.64 +0.56 (+7.91%) Closing price 04:00 PM EasternExtended Trading$7.64 0.00 (-0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Bioventus Stock (NYSE:BVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioventus alerts:Sign Up Key Stats Today's Range$7.08▼$7.7450-Day Range$6.14▼$7.5352-Week Range$5.81▼$14.38Volume603,873 shsAverage Volume399,140 shsMarket Capitalization$631.67 millionP/E RatioN/ADividend YieldN/APrice Target$13.75Consensus RatingModerate Buy Company Overview Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina. Read More Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address BVS Stock News HeadlinesCraig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PTAugust 13, 2025 | msn.comCanaccord Genuity Sticks to Its Buy Rating for Bioventus (BVS)August 12, 2025 | theglobeandmail.com"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity.August 22 at 2:00 AM | Crypto 101 Media (Ad)Brokers Set Expectations for Bioventus FY2025 EarningsAugust 12, 2025 | americanbankingnews.comBioventus to Present at the Canaccord Genuity 45th Annual Global Growth ConferenceAugust 7, 2025 | globenewswire.comBioventus Inc. (BVS) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comBioventus Inc. Reports Q2 2025 Financial ResultsAugust 7, 2025 | tipranks.comBioventus Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 6, 2025 | seekingalpha.comSee More Headlines BVS Stock Analysis - Frequently Asked Questions How have BVS shares performed this year? Bioventus' stock was trading at $10.50 at the start of the year. Since then, BVS stock has decreased by 27.2% and is now trading at $7.64. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) released its earnings results on Tuesday, November, 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million for the quarter, compared to analysts' expectations of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 15.61%. When did Bioventus IPO? Bioventus (BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO. Who are Bioventus' major shareholders? Top institutional investors of Bioventus include Nantahala Capital Management LLC (6.43%), American Century Companies Inc. (1.37%), Divisadero Street Capital Management LP (1.32%) and Geode Capital Management LLC (1.28%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, Mark Leonard Singleton, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Robert E Claypoole, Katrina J Church and Kenneth Michael Reali. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioventus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings11/05/2024Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:BVS CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Price Target for Bioventus$13.75 High Price Target$15.00 Low Price Target$12.00 Potential Upside/Downside+94.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio17.27 P/E GrowthN/ANet Income-$156.23 million Net Margins-7.11% Pretax Margin-10.41% Return on Equity15.61% Return on Assets4.01% Debt Debt-to-Equity Ratio1.85 Current Ratio1.41 Quick Ratio0.99 Sales & Book Value Annual Sales$564.14 million Price / Sales1.04 Cash Flow$0.56 per share Price / Cash Flow12.58 Book Value$2.80 per share Price / Book2.53Miscellaneous Outstanding Shares82,679,000Free Float54,455,000Market Cap$585.37 million OptionableNot Optionable Beta0.83 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:BVS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.